1. Medtech Insight
  2. >>Device Area

The View Beyond LASIK: New Techs Further Propel Refractive Surgical Market

 
• By Bob Kronemyer

LASIK continues to hold a dominant share of the refractive surgical market but limitations in current technologies are stymying further growth. However, a tide of innovation refractive correction is coming in now, and over the next few years that will accelerate growth in this market and fully capitalize on this huge and yet undertapped opportunity known as presbyopia. This article discusses drivers and barriers in the refractive correction market and highlights three companies to look out for this space.

close up of an eye
New technologies in refractive vision correction • Source: shutterstock.com

Apart from traditional eyeglasses and contact lenses, laser-assisted in situ keratomileusis (LASIK) remains the dominant method globally for correcting refractive errors. However, this corneal refractive laser surgery procedure is not ideal, due to the fact that it is invasive, rarely can be repeated, corrects only distance vision and requires a huge capital expenditure.

Still, LASIK is big business. According to 2015 data from Market Scope LLC, the national average cost of LASIK in the US is $2,259 per eye, it is estimated that...

Outside the US and Europe, China has experienced dramatic growth in LASIK. In 2013, the country performed 950,000 procedures, representing $713m in associated revenue, according to the Forecast of Laser...

More from Ophthalmology

More from Device Area

FDLI: Clinical Labs Face Uncertainty After Texas Court’s LDT Ruling

 
• By Elizabeth Orr

A Texas court's decision against US FDA regulation of lab-developed tests (LDTs) has introduced new uncertainties for clinical labs. Industry stakeholders are now worried about potential future regulations while also managing existing compliance requirements. Recent conference discussions underscored the complexities of FDA oversight.

Data Finds Capillary Blood Is A Reliable Alternative To Venous Blood For Routine Testing

 
• By Natasha Barrow

A study from Babson Diagnostics published in the peer-reviewed Journal of Applied Laboratory Medicine showed that capillary blood sample volume issues can overcome historical challenges, such as poor quality, through a technique called assay miniaturization.

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 
• By Natasha Barrow

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.